Newmanbrain

Newmanbrain operates at the intersection of medical devices, healthcare software, and neurotechnology. Its differentiation is centered on portable functional near-infrared spectroscopy (fNIRS): THEIA™ is described as measuring brain activity and supporting cognitive assessment, while the company’s documented technical work includes methods for obtaining cerebral signals and selecting functional biomarkers. This gives Newmanbrain a distinct approach from companies focused primarily on questionnaire-based mental-health screening or general-purpose digital health software. The available company profile does not identify named competitors or provide enough detail to make a reliable company-by-company comparison; similar-company entries do not identify independent peers. Its market position therefore appears best characterized by its specialized measurement technology and intended cognitive-assessment use, rather than by demonstrated market share or commercial scale. Newmanbrain is listed as a private company founded in 2018, with an employee range of 1–10 and categories spanning Health Care, Medical Device, and Software. Public information does not establish comparative clinical performance, regulatory status, sales, or adoption, so these factors cannot be used to assess its competitive standing.

Newmanbrain’s trajectory reflects a focused progression from neurotechnology development toward a portable cognitive-assessment product. Founded in 2018, the company has built around fNIRS-based measurement of brain activity. Its documented technical milestones include a cerebral-signal method dated Apr 14, 2022, a functional-biomarker selection method dated Dec 27, 2023, and another near-infrared brain-signal method dated Feb 6, 2024. The Jul 25, 2024 coverage connecting its near-infrared spectroscopy work with ADHD diagnosis marks a point of public attention for a potential clinical application. Product information identifies THEIA™ as a portable device with AI-powered analytics for cognitive assessment, representing a product direction beyond instrumentation alone. As a result, the evidence supports ongoing technical and product development, but does not establish commercialization pace, revenue growth, or clinical adoption.